Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 7, 2018Expert Opinion on Drug Safety

The safety of pharmacologic treatment for pediatric obesity

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAriana M. ChaoJohns Hopkins UniversityThomas A. WaddenThomas A. WaddenUniversity of PennsylvaniaRBRobert I. BerkowitzBrigham and Women's Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chao et al. (2018) studied this question.

synapsesocial.com/papers/6a88511afc0635f4eccf0f33https://doi.org/10.1080/14740338.2018.1437143
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study1998 · 659 citations
  2. 2Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension1996 · 1,174 citations
  3. 3Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events2016 · 875 citations
  4. 4Tracking of BMI z Scores for Severe Obesity2017 · 168 citations
  5. 5Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)2011 · 726 citations